Delivery type not associated with global methylation at birth by unknown
Virani et al. Clinical Epigenetics 2012, 4:8
http://www.clinicalepigeneticsjournal.com/content/4/1/8RESEARCH Open AccessDelivery type not associated with global
methylation at birth
Shama Virani1, Dana C Dolinoy1, Sindhu Halubai2, Tamara R Jones1, Steve E Domino3, Laura S Rozek1,4,
Muna S Nahar1 and Vasantha Padmanabhan2,3*Abstract
Background: Birth by cesarean delivery (CD) as opposed to vaginal delivery (VD) is associated with altered health
outcomes later in life, including respiratory disorders, allergies and risk of developing type I diabetes. Epigenetic gene
regulation is a proposed mechanism by which early life exposures affect later health outcomes. Previously, type of delivery
has been found to be associated with differences in global methylation levels, but the sample sizes have been small. We
measured global methylation in a large birth cohort to identify whether type of delivery is associated with epigenetic
changes.
Methods: DNA was isolated from cord blood collected from the University of Michigan Women’s & Children Hospital and
bisulfite-converted. The Luminometric Methylation Assay (LUMA) and LINE-1 methylation assay were run on all samples in
duplicate.
Results: Global methylation data at CCGG sites throughout the genome, as measured by LUMA, were available from 392
births (52% male; 65% CD), and quantitative methylation levels at LINE-1 repetitive elements were available for 407 births
(52% male; 64% CD). LUMA and LINE-1 methylation measurements were negatively correlated in this population
(Spearman’s r =−0.13, p =0.01). LUMA measurements were significantly lower for total CD and planned CD, but not
emergency CD when compared to VD (median VD=74.8, median total CD=74.4, p=0.03; median planned CD=74.2,
p=0.02; median emergency CD=75.3, p=0.39). However, this association did not persist when adjusting for maternal
age, maternal smoking and infant gender. Furthermore, total CD deliveries, planned CD and emergency CD deliveries
were not associated with LINE-1 measurements as compared to VD (median VD=82.2, median total CD=81.9, p=0.19;
median planned CD=81.9, p=0.19; median emergency CD=82.1, p=0.52). This lack of association held when adjusting
for maternal age, maternal smoking and infant gender in a multivariable model.
Conclusions: Type of delivery was not associated with global methylation in our population, even after adjustment for
maternal age, maternal smoking, and infant gender. While type of birth may be associated with later health outcomes,
our data suggest that it does not do so through changes in global genomic methylation.
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Infant stress during labor is advantageous in preparation
for extrauterine life; however, the stress encountered by
infants varies vastly between delivery types. The progres-
sion of labor involves a surge in stress hormones, includ-
ing catecholamines and cortisol, in the infant to promote
lung maturity for gas exchange, increase blood flow,* Correspondence: vasantha@umich.edu
2Department of Pediatrics, The University of Michigan, Ann Arbor, MI, USA
3Department of Obstetrics and Gynecology, The University of Michigan, Ann
Arbor, MI, USA
Full list of author information is available at the end of the article
© 2012 Virani et al.; licensee BioMed Central L
Commons Attribution License ( http://creativeco
reproduction in any medium, provided the origactivate the central nervous system and mobilize fuel
[1,2]. This high release of stress hormones also triggers a
cascade of hormones and cytokines involved in inflam-
matory defense pathways [1,3]. Uncomplicated vaginal
deliveries (VDs) undergo a normal progression of labor
in which the infant experiences these critical changes;
however, elective cesarean deliveries (CDs) do not, and
infants born via this CD typically lack the necessary
surges of hormone release. In emergency CDs, labor may
be incomplete and the full release of hormones may not
occur. Comparison of these different delivery typestd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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mone release [1,2,4–6] as well as a greater number of in-
testinal flora [7] and higher immune response [8] than
those born through elective CD. Emergency CD infants
have higher hormone levels than those born via elective
CD, but lower than those born via VD [9].
Surges of stress hormones during labor progress devel-
opment of essential pathways that will enable the infant
to survive outside the womb, thus implicating changes in
the genome in response to stress. However, these
changes may not occur if the infant does not undergo
such stress, such as during a CD. The increasing number
of CDs has led to scrutiny of the impact that type of de-
livery has on infant health and predisposition to disease
outcomes. Birth via CD is associated with a higher risk
of developing diseases such as allergic rhinoconjunctivitis
and asthma [10,11], type 1 diabetes [12], respiratory dis-
orders [13] and pediatric Crohn’s disease [14].
The molecular mechanisms associated with these phe-
nomena remain unknown; however, emerging evidence
suggests that when an infant does not develop essential
defense mechanisms, he or she may be predisposed to
developing disease later on in life. The developmental
origins of health and disease (DOHaD) hypothesis posits
that increased susceptibility to disease following early life
experiences is shaped by epigenetic modifications such
as DNA methylation and chromatin modifications [15].
Epigenetics allows for adaptive responses of the genome
to an ever-changing environment by modifying transcrip-
tional regulation of gene expression. These adaptations
are achieved in response to developmental stage, envir-
onmental exposures and cell differentiation. Due to the
pliability of the epigenome in response to surroundings,
such as delivery environment, altered fetal or neonatal
epigenetic modifications may play a role in later-life dis-
ease susceptibility [16–18]. While many types of epigen-
etic modifications occur, DNA methylation is the most
extensively studied. Because DNA methylation is inher-
ited in somatic cells, early epigenetic events can have
lasting effects on gene expression, which may in turn
provide the molecular basis for susceptibility to disease
later in life [17].
A disease outcome likely results from aberrant activity
of many different molecular pathways, and thus it is
likely that epigenetic modifications occur at multiple
genes or genic regions. Measurement of global DNA
methylation patterns is a practical means of identifying
differential epigenetic effects in neonates. Furthermore,
recent research has shown differential global methylation
between CD and VD infants, although the sample size
was small [19].
The objectives of this study are to (1) confirm the appar-
ent difference in global DNA methylation between infants
born via CD as compared to VD in white blood cells fromcord blood in a large population, using two separate global
DNA methylation measurements and (2) determine if
methylation differences are associated with type of CD (for
example, scheduled versus emergency) as compared to VD.
Methods
Study population
IRB approval was obtained for the purpose of collecting
excess cord blood samples from our study population,
which consisted of 408 infants (> 37 weeks) delivered at
the University of Michigan Women’s & Children Hospital.
Only pregnancies occurring between 8 a.m. and 2 p.m.
were included to provide more time for sample processing,
and included scheduled and emergency CDs as well as
VDs. Because this study collected excess clinical samples,
samples were obtained from all deliveries during this time
period. Samples were collected with few exclusion criteria,
only requiring singleton pregnancy and clinically excess
tissue available immediately after delivery in order to
maximize sample quality. After delivery of the placenta,
the umbilical cord was clamped, washed thoroughly to
prevent maternal blood contamination, and whole venous
blood was drawn via venipuncture into PAX gene Blood
DNA tubes (Qiagen Inc., Valencia, CA), kept on ice and
transported to the laboratory.
DNA isolation and bisulfite conversion
Genomic DNA was extracted using the PAX gene
Blood DNA kit (PreAnalytiX/Qiagen, Hombrechtikon,
Switzerland). Leukocyte DNA was isolated following
the manufacturer’s protocol with some minor modifi-
cations for dense blood. For complete digestion of
dense samples, the initial 65°C incubation period was
increased from 10 min to 1 h. The final incubation
of the solution was repeated a second time in order
to completely dissolve the DNA containing pellet in
elution buffer. Both the quality and quantity of the
extracted DNA were assessed using a ND1000 spec-
trophotometer (NanoDrop Technology, Wilmington,
DL). For bisulfite conversion, the addition of sodium
bisulfite selectively deaminates unmethylated cytosine
nucleotides into uracil whereby a subsequent poly-
merase chain reaction (PCR) incorporates thymine,
leaving methylated cytosines unchanged. Complete
bisulfite modification of genomic DNA results in
methylation-dependent genome-wide alterations in
DNA sequences. Approximately 1 μg of genomic
cord blood DNA was bisulfite converted using the
EpiTect Bisulfite Kit (Qiagen Inc., Valencia, CA) and
QIAcubeW purification system.
LUMA and LINE-1 assays
The Luminometric Methylation Assay (LUMA) is a restric-
tion enzyme-based procedure that detects methylation at
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of methylation at repetitive elements. The procedure for
LUMA analysis via pyrosequencing has been previously
described [20,21]. Briefly, approximately 5 units of
methylation-insensitive MspI (Biolabs) and of methylation-
sensitive HpaII (Biolabs) enzymes were separately added to
300 ng of genomic DNA along with the internal standard
EcoRI (Biolabs) enzyme and 10× buffer.
Tango™with BSA (Fermentes) was used for differential di-
gestion. Samples were incubated at 37°C for 4 h. Twenty μl
of annealing buffer was added prior to pyrosequencing in
AQ mode using the SNP PyroMarkMD software with the
following dispensation order: GTGTCACATGTGTG. The
ratio of normalized product signal between methylation-
sensitive and -insensitive digestions from an individual sam-
ple was measured to calculate global DNA methylation
using the following equation: 1− [(HpaII/EcoRI)/(MspI/
EcoRI)] × 100. Individual samples were run in duplicate
along with lowly and highly methylated human genomic
standards (EpigenDx).
The LINE-1 assay interrogates promoter DNA methyla-
tion of repetitive elements, specifically long interspersed
(LI) retrotransposons, throughout the genome [22]. Fifty
ng/μl of bisulfite converted DNA was used in a PCR mix
containing water, HotStarTaq master mix (Qiagen), (1
pmol) LINE-1 forward and (0.5 pmol) LINE-1 biotin-
labeled reverse primers, followed by amplification via spe-
cific PCR cycling parameters: 95°C for 14.5 min (Hot
Start), 95°C for 30 s, 58°C for 30 s, 72°C for 30 s at 45
cycles. We also included bisulfite-converted DNA from
lowly and highly methylated controls. Amplified products
were verified using gel electrophoresis. LINE-1 amplified
products were analyzed in duplicate using the
PyroMark™Q96 MD Pyrosequencing System (Pyrosequen-
cing, Inc., Westborough, MA) and a predetermined se-
quence-to-analyze run. Approximately 15 μl of LINE-1
PCR product was added with LINE-1 sequencing primers.
Methylation analysis by pyrosequencing was conducted as
previously described [23]. The following modified primers
(Invitrogen) [22] were used for the complete assessment:
LINE-1 forward primer: 5’-TTG AGT TAG GTG TGG
GAT ATA GTT-3’; reverse primer: 5’-CAA AAA ATC
AAA AAA TTC CCT TTC C-3’; sequencing primer: 5’-
AGG TGT GGA TAT AGT-3’; sequence to analyze: TT
[T/C]GTGGTG[T/C]GT[T/C]GTTTTTTAAGT[T/C]GG
TTTGAAAAG. The PyroMark Q-CpG software computes
the ratio of cytosine and thymine signal intensity at each
of the four CpG sites in this assay, referenced as site 1, 2, 3
and 4, and outputs a % methylation value for DNA methy-
lation analysis of LINE-1 global and gene-specific assays.
Statistical analysis
Duplicate LUMA and LINE-1 global methylation mea-
surements were averaged for all analyses, and duplicatesresulting in a greater than 15% difference were deleted
before statistical analysis, leading to 16 subjects deleted
for LUMA and 1 deleted for LINE-1. Due to departures
from normality, data are expressed as median values and
ranges. Bivariate nonparametric tests (Wilcoxon rank
sum test and Kruskal-Wallis test) were used to test the
association between global methylation (LUMA and
LINE-1) and covariates (type of delivery, infant gender,
maternal age, maternal smoking). Significance of correla-
tions between covariates was tested using Spearman’s
correlation. Generalized linear models were used to test
the association between type of deliveries with each
methylation measurement, adjusting for maternal age,
maternal smoking status and infant gender. Mixed
effects models were used to test the association between
each specific LINE-1 site (site 1, site 2, site 3 and site 4)
to account for covariance between measurements. Statis-
tical significance was set at p< 0.05. Generalized linear
models were run in R version 2.12.0 (R Development
Core Team, 2010), and mixed effects models were run in
SAS 9.2 (Cary, NC).
Results
Descriptive statistics
Data were available for 408 subjects. Thirty-six percent
were VDs, while 64% delivered via CD. Of the CD deliver-
ies, 80% were planned CD deliveries, and 20% were emer-
gency CD deliveries. Maternal age ranged from 18–48
years, with approximately equal male and female infants
(52%, 48%, respectively). The majority of mothers did not
have a history of smoking (60%), while 11% were past smo-
kers and 6% were current smokers; for 93 of the 408 sub-
jects, smoking status was unknown (Table 1). There were
significant correlations between age and type of delivery as
well as smoking and type of delivery; however, the magni-
tude of the correlations was low (rho=0.2, 0.1, p< 0.001,
p=0.03, respectively).
Global methylation at CCGG sites (LUMA)
Among the sample population, the median LUMA meas-
urement was 74.5% (46.3-83.6), and mean LUMA meas-
urement was 73.8% (Table 1). In comparing VD with
total CD (planned and emergency combined), CD deliv-
eries had significantly lower LUMA methylation than
VD (median CD=74.4, median VD=74.8, p= 0.03);
however, this association did not persist after adjustment
for maternal age, maternal smoking and infant gender
(Table 2).
When comparing types of CDs with VD, LUMA mea-
surements in infants born via planned CS were signifi-
cantly lower than in infants born through VD [median
VD=74.8 (56.4-83.6), median planned CD=74.2 (46.3-
81.6), p= 0.02]. There was no difference in methylation
between VD and emergency CDs [median emergency
Table 1 Global methylation by delivery characteristics
LUMA (%) LINE1-1 (%) LINE1-2 (%) LINE1-3 (%) LINE1-4 (%) Mean LINE1
Features No. Median (range) Mean No. Median (range) Mean Median (range) Mean Median (range) Mean Median (range) Mean Median (range) Mean
Overall 392 74.5 (46.3-83.6) 73.8 407 85.1 (72.7-98.7) 84.5 82.7 (74.1 95.0) 82.2 81.6 (71.3-98.7) 81.4 78.6 (71.8-97.0) 78.4 82.0 (73.6-97.4) 81.6
Type of delivery
Vaginal 254 74.4 (46.3-81.6) 73.5 262 85.1 (72.7-90.6) 84.3 82.6 (74.1-87.2) 82.2 81.4 (71.3-90.6) 81.2 78.4 (71.9-90.5) 78.3 81.9 (74.9-85.7) 81.5
Planned CD 201 74.2 (46.3-81.6) 73.4 207 85.1 (72.7-90.4) 84.4 82.6 (75.5-87.2) 82.2 81.3 (71.3-90.6) 81.2 78.4 (71.9-89.2) 78.3 81.9 (74.9-85.6) 81.5
Planned CD 53 75.3 (56.6-79.2) 73.9 55 85.0 (76.2-90.6) 84.3 82.8 (74.1-85.6) 82.1 81.7 (74.3-85.9) 81.4 78.4 (72.0-90.5) 78.5 82.1 (76.1-85.7) 81.6
Emergency CD 138 74.8 (56.4-83.6) 74.5 145 85.3 (73.8-98.7) 84.7 82.7 (74.3-95.0) 82.3 82.1 (71.8-98.7) 81.7 78.9 (71.8-97.0) 78.6 82.2 (73.6-97.4) 81.8
Infant gender
Male 203 74.6 (46.3-83.6) 73.5 213 85.0 (73.8-98.7) 84.3 82.6 (75.5-90.0) 82.2 81.5 (71.3-98.7) 81.5 78.7 (71.9-97.0) 78.7 82 (76.3-97.4) 81.7
Female 188 74.4 (55.5-83.6) 74.2 193 85.3 (72.7-90.7) 84.7 82.8 (74.1-87.2) 82.3 81.7 (71.8-85.5) 81.3 78.5 (71.8-83.9) 78.2 82.1 (73.6-85.6) 81.62
Smoking
Never 234 74.6 (46.3-83.6) 73.8 243 85.1 (72.7-90.4) 84.3 82.6 (75.5-87.6) 82.1 81.3 (71.3-86.7) 81.2 78.4 (71.8-90.5) 78.2 81.9 (75.5-85.6) 81.4
Past 44 75.1 (59.3-81.0) 74.1 45 85.0 (73.8-91.8) 84.8 82.7 (74.1-85.6) 82.1 81.5 (74.5-89.3) 81.1 78.4 (74.6-83.9) 78.2 82.2 (76.1-87.3) 81.6
Current 24 73.9 (64.7-81.6) 73.9 26 85.3 (78.3-98.7) 85.6 82.5 (75.9-95.0) 82.5 81.8 (75.0-98.7) 82.4 79.7 (75.8-97.0) 80.3 82.5 (77.4-97.4) 82.7
Age
18-27 111 75.0 (59.3-83.6) 74.5 117 84.8 (72.8-98.7) 83.9 82.6 (74.1-95.0) 82.1 82.0 (71.8-98.7) 81.5 78.7 (71.8-97.0) 78.3 82.0 (73.6-97.4) 81.5
28-37 232 74.3 (46.3-81.6) 73.6 241 85.4 (72.7-91.8) 84.8 82.8 (75.7-87.6) 82.3 81.5 (71.3-90.6) 81.4 78.7 (72.4-90.5) 78.6 82.1 (75.5-87.3) 81.8













Table 2 Association between all types of deliveries and global DNA methylation measurements Association between
delivery types and global DNA methylation
VDa Total CDb Planned CD Emergency CD
β (95% CI) β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value p-value
for trendd
MeanLUMA n=138 n=254 n=201 n=53
Crude 1.00 −1.01 (−1.90, -0.12) 0.03 −1.12 (−2.05, -0.19) 0.02 −0.60 (−1.96, 0.77) 0.39 0.12
Model 1c 1.00 −0.91 (−1.99, 0.17) 0.1 −1.00 (−2.11, 0.12) 0.08 −0.53 (−2.16, 1.10) 0.54 0.28
MeanLINE-1 n=145 n=262 n=207 n=55
Crude 1.00 −0.31 (−0.78, 0.16) 0.19 −0.33 (−0.82, 0.16) 0.19 −0.24 (−0.95, 0.48) 0.52 0.32
Model 1ce 1.00 −0.31 (−0.78, 0.15) 0.27 −0.32 (−0.89, 0.25) 0.28 −0.30 (−1.14, 0.54) 0.48 0.30
aReference category.
bIncluding both planned and emergency CD.
cAdjusted for maternal smoking, maternal age and infant gender.
dTrend among VD, planned CD and emergency CD.
eCurrent smokers p-value< 0.05.
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ternal age, maternal smoking and infant gender, LUMA
methylation measurements in infants born via planned
CD were still lower than those found in infants born via
VD; however, this result was not significant (p= 0.08) in
the multivariable model. There was no difference in
methylation between emergency CD and total CD with
VD infants after adjusting for covariates (p= 0.28)
(Table 2). Point estimates for type of deliveries were al-
most as large as before adjustment, but were no longer
significant after adjustment for maternal age, maternal
smoking and infant gender. The magnitude of effect for
the covariates may explain this observation (Table 3).
Methylation at LINE-1 repetitive elements
The median LINE-1 methylation for the sample popula-
tion was 82.0% (range: 73.6-97.4), and the mean was
81.6% (Table 1). In comparing total CDs with VD, there
was no difference found in LINE-1 methylation
(p= 0.19). This result did not change after adjustment for
maternal age, maternal smoking and infant gender
(p= 0.27) (Table 2). There was also no difference in mean
LINE-1 methylation in infants born via planned CD [me-
dian = 81.9 (74.9-85.6), p= 0.19] and via emergency CDTable 3 Magnitude of effects for covariates
Mean LUMA Mean LINE-1
β (95% CI) p-value β (95% CI) p-value
Maternal age −0.04 (−0.13, 0.05) 0.42 −0.04 (−0.08, 0.01) 0.13
Infant gendera 0.68 (−0.30, 1.66) 0.17 0.06 (−0.44, 0.57) 0.80
Former smokerb 0.24 (−1.20,1.68) 0.74 0.17 (−0.58, 0.92) 0.66
Current smoker
b 0.15 (−1.71, 2.01) 0.87 1.12 (0.18, 2.07) 0.02*
aReference category =male.
bReference category = never smokers.
*p-value< 0.05.[median = 82.1 (76.1-85.7), p= 0.52] compared to those
born through VD [median = 82.2 (73.6-97.4)] (Table 2).
These results did not change after adjustment for mater-
nal age, maternal smoking and infant gender. Point esti-
mates for adjusted and unadjusted models were similar,
implicating that these covariates may influence LINE-1
methylation (Table 3).
Comparing individual sites within LINE-1, sites 2, 3
and 4 all had significantly lower methylation than site 1
(p=< 0.001 for all). Type of delivery was not associated
with methylation of any individual LINE-1 site (Table 4).
These results did not change after adjustment for mater-
nal age, maternal smoking and infant gender. For mean
LINE-1 and all individual LINE-1 sites, infants born to
mothers who reported current smoking had significantly
higher methylation compared to infants born to mothers
without a history of smoking (p= 0.02). This was seen in
both crude and adjusted models of smoking.
LUMA and LINE-1 measurements were negatively cor-
related (Spearman’s r =−0.13, p= 0.01). The coefficient of
variation for LUMA was 5.86%, and the coefficient of
variation for LINE-1 was 2.82%. When statistical analyses
were restricted to individuals with both measures
(n= 392) similar results were observed (data not shown).
Discussion
It is crucial to study epigenetic modifications in an early
life context to better understand their influence on an
individual’s risk of developing disease later in life. Infant
delivery is a prominent early life event involving major
hormonal changes. In VDs, infants undergo high stress
levels, as indicated by the elevation of stress hormones
[24] and increase in immune function [8] as compared
to those delivered via CD. This sudden increase in stress
and immune activation may correspond to a change in
environment, potentially inducing adaptive modifications
Table 4 Association between type of delivery and Line-1 sites
VDa Total CDb Planned CD Emergency CD
β (95% CI) β (95% CI) p-value β (95% CI) p-value β (95% CI) p-value p-value
for trendd
Crude n=145 n=262 n=207 n=55
Site 1 1.00 1.00 1.00 1.00
Site 2 1.00 0.26 (−0.31, 0.83) 0.37 0.27 (−0.33, 0.86) 0.38 0.22 (−0.64, 1.09) 0.62 0.47
Site 3 1.00 −0.06 (−0.51, 0.62) 0.84 −0.11 (−0.71, 0.48) 0.71 0.16 (−0.71, 1.02) 0.72 0.88
Site 4 1.00 0.05 (−0.52, 0.61) 0.87 −0.02 (−0.57, 0.62) 0.94 0.31 (−0.56, 1.18) 0.48 0.60
Adjustedc
Site 1 1.00 1.00 1.00 1.00
Site 2 1.00 0.20 (−0.46, 0.86) 0.55 0.22 (−0.47, 0.90) 0.54 0.14 (−0.87, 1.15) 0.79 0.66
Site 3 1.00 −0.37 (−0.29, 1.03) 0.27 −0.43 (−1.11, 0.26) 0.23 −0.16 (−1.17, 0.85) 0.75 0.49
Site 4 1.00 −0.11 (−0.77, 0.54) 0.73 −0.19 (−0.88, 0.50) 0.59 0.17 (−0.84, 1.18) 0.74 0.95
Mixed effects model.
aReference category.
bIncluding both planned and emergency CD.
cAdjusted for maternal smoking, maternal age and infant gender.
dTrend among VD, Planned CD and emergency CD.
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ferences resulting from type of delivery to determine if
global DNA and repetitive element methylation changes
could be the molecular mechanism for disease suscepti-
bility later in life. Global methylation levels can be mea-
sured in multiple ways, and in our study, global
methylation at CCGG was negatively correlated with glo-
bal repetitive element methylation at LINE-1 sites. LINE-
1 measurements of global repetitive element methylation
provide an index of genomic instability. The LINE-1
assay measures methylation of the LINE-1 retrotranspo-
sons that make up approximately 17% of the human gen-
ome; however, only about 3,000-5,000 of these elements
are actively transposing within the genome [25].
Methylation of LINE-1 elements is crucial to suppress
their retrotransposition, minimizing insertion into essen-
tial genes or promoters that would cause genomic in-
stability. LINE-1 methylation measurements are a
general indication of the amount of genomic instability
that may occur when global methylation levels are low.
Our results show no significant difference in LINE-1
mean methylation or LINE-1 site-specific methylation
between CD and VD births. When CDs were further
categorized into planned and emergency CD, no signifi-
cant differences in LINE-1 methylation levels were
observed, even when adjusting for infant gender, mater-
nal smoking and maternal age.
A second option for global methylation measurement
is the LUMA method [20,21]. LUMA measures methyla-
tion at CCGG sites throughout the entire genome re-
gardless of location, illustrating global methylation at
these sites. The amount of LUMA methylation may have
implications for levels of gene expression across variouscellular pathways and is often indicative of pathological
processes [20,21]. Our delivery type analysis indicates
that LUMA measurements are significantly lower for
CDs than VDs, although this association does not persist
after adjusting for maternal age, maternal smoking and
infant gender. In further categorizing CDs, there are no
differences between emergency CD and VD, but planned
CDs had significantly lower methylation compared to
VDs. This association, however, does not persist when
adjusting for maternal age, maternal smoking and infant
gender. Although the association was attenuated, the
pattern of lower global methylation in planned CD
infants is seen in both the crude and adjusted models,
indicating that a significant association may be achieved
with a larger sample size for subgroup analyses. How-
ever, the crude analysis for the LUMA assay may be the
most appropriate for understanding global methylation
as a result of delivery type. If maternal age or smoking is
the driving force behind this association, then global
methylation might be an intermediate variable between
these predictors and type of delivery, which may attenu-
ate some of the effect for LUMA. Even if smoking or ma-
ternal age is upstream from LUMA with respect to the
causal pathway, both are likely to have multiple mechan-
isms of action, including methylation and other non-
epigenetic mechanisms. Additionally, birth weight could
be added into the model. A recently published study
reported that birth weight and prematurity are associated
with lower LINE-1 methylation [26].
A previous study conducted by Schlinzig et al. [19]
analyzing the relationship between type of delivery and
LUMA measurements reported significantly higher
methylation in infants delivered by elective CD than
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after birth. Our results of lower methylation in planned
CDs conflict with the previous study’s findings of higher
methylation in elective CDs. However, specific aspects of
the individual study designs that differ may explain the
discrepancy. Schlinzig et al. used a population of 37
infants from Stockholm, Sweden, whereas we assessed a
population of 408 infants from Ann Arbor, Michigan.
Population differences, sampling variance or both may
play a role in the distinctive findings. With our large
sample size we provide adequate power to our results.
The LINE-1 mean and site-specific models adjusted for
maternal age, maternal smoking and infant gender con-
sistently indicate that current maternal smokers deliver
infants with significantly higher methylation than those
born from mothers who never smoked, although the ef-
fect is modest. This association between smoking and
LINE-1 methylation is significant in both crude and
adjusted models. These results indicate that smoking has
an effect on LINE-1 methylation as established by previ-
ous literature, although the direction of effect has
remained inconclusive [27,28]. In our study, LINE-1
methylation was higher for infants born from current
smokers as compared to infants born from non-smokers,
although smoking did not differ by delivery type. A limi-
tation in our study is the low prevalence of current
smoking in this sample of women (6%). The prevalence
of current smoking in the US population is around 20%
[29]. It is possible that our subgroup of smokers was too
small to detect an association between smoking and
methylation due to type of delivery.
Conclusions
In summary, no differences in global DNA or repetitive
element methylation of cord-blood derived leukocytes were
observed in infants delivered via planned CD or emergency
CD as compared to those delivered vaginally. A strength of
this study is a strong foundation for future investigations,
namely the large sample size, categorization of CDs into
planned and emergency types, and the use of two separate
global methylation measurement techniques. This approach
not only provides power to the study, but also takes into ac-
count the different types of stress from delivery on the in-
fant. A limitation of this study is the lack of longitudinal
post-delivery epigenetic measurements. Methylation pat-
terns may change over time, and such data would be useful
for future epigenetic epidemiology study considerations.
The evaluation of methylation profiles should be investi-
gated across multiple time points, as it is possible the type-
of-delivery effects on the epigenome manifest later in life.
Although this study provides negative findings when asses-
sing global genomic methylation patterns, it does not dis-
count the potential for delivery type to affect the infant
epigenome in a gene-specific manner. Future studies shouldfocus on candidate gene methylation changes in pathways
involved in diseases associated with CDs.
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